Evaxion Announces Financing Commitments Totaling Up To Usd 20 Million With Negma Group
08/01/23, 11:12 AM
Location
copenhagenIndustry
biotechnology
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that it has entered into a binding agreement for a financing of up to USD 20 million with Negma Group Investment Ltd, a Paris-based leading financial institution focused on supporting growth and capturing value through a multi-strategy approach.
Company Info
Location
copenhagen, capital region of denmark, denmark
Additional Info
We are a clinical-stage AI-immunology™ platform company using our proprietary artificial intelligence, or AI, technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections.
We are currently in the clinic with our two lead product candidates, EVX-01 and EVX-02, for the treatment of various cancers.
We have three proprietary AI platforms: PIONEER, our immuno-oncology platform, EDEN, our bacterial disease platform, and RAVEN, our viral disease platform.